Work Schedule
Standard (Mon-Fri)
Environmental Conditions
Office
Thermo Fisher Scientific recently announced that it has entered into an agreement to sell its microbiology business to Astorg, a leading pan-European private equity firm with deep expertise in healthcare, focused on a select set of subsectors, including pharmaceutical services and technology, medtech and related services, life science tools and diagnostics.
This decision follows a thoughtful evaluation as part of Thermo Fisher’s ongoing business strategy to actively manage and strengthen our portfolio.
We expect the transaction will be completed in the second half of 2026, subject to customary closing conditions and applicable regulatory approvals. Until the transaction is complete, Thermo Fisher will continue to operate the business.
If you join the microbiology business prior to the close of the transaction, your employment is expected to transition to Astorg.
For more information, please review:
A Day in the Life:
Keys To Success:
Education:
Experience
Knowledge, Skills, Abilities

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
For more information, please visit www.thermofisher.com.